169 related articles for article (PubMed ID: 26672785)
1. Metastasis: Resistance fighters.
Savage N
Nature; 2015 Dec; 528(7582):S128-9. PubMed ID: 26672785
[No Abstract] [Full Text] [Related]
2. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
4. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
5. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
Antonarakis ES
Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
[TBL] [Abstract][Full Text] [Related]
6. [Splicing variant of androgen receptors (AR-V7): New paradigms].
Penel N
Bull Cancer; 2016 Sep; 103(9):711-3. PubMed ID: 27591905
[No Abstract] [Full Text] [Related]
7. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
Penning TM
J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
[TBL] [Abstract][Full Text] [Related]
9. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
[No Abstract] [Full Text] [Related]
10. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
11. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
Dhawan M; Ryan CJ
Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
Tombal B
Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
[No Abstract] [Full Text] [Related]
13. Secondary hormone therapy for castration-resistant prostate cancer.
Taplin ME
Oncology (Williston Park); 2013 May; 27(5):371-2. PubMed ID: 25184257
[No Abstract] [Full Text] [Related]
14. Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Shao N; Zhu Y; Ye DW
Eur Urol Focus; 2019 Sep; 5(5):745-747. PubMed ID: 30797739
[TBL] [Abstract][Full Text] [Related]
15. New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer.
Assi R; Temraz S; Shamseddine A; Mukherji D
Curr Drug Targets; 2016; 17(3):290-302. PubMed ID: 26343110
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
17. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.
He Y; Peng S; Wang J; Chen H; Cong X; Chen A; Hu M; Qin M; Wu H; Gao S; Wang L; Wang X; Yi Z; Liu M
Nat Commun; 2016 Dec; 7():13122. PubMed ID: 27959342
[TBL] [Abstract][Full Text] [Related]
18. New targets for resistant prostate cancer.
Thompson TC; Li L
Oncotarget; 2014 Oct; 5(19):8816-7. PubMed ID: 25301740
[No Abstract] [Full Text] [Related]
19. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Baillie K; Mueller T; Pan J; Laskey J; Bennie M; Crearie C; Kavanagh K; Alvarez-Madrazo S; Morrison D; Clarke J; Keel A; Cameron D; Wu O; Kurdi A; Jones RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):653-663. PubMed ID: 32316077
[TBL] [Abstract][Full Text] [Related]
20. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]